Landos Biopharma Inc
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $3.302
- Today's High:
- $3.63
- Open Price:
- $3.63
- 52W Low:
- $2.11
- 52W High:
- $11.5
- Prev. Close:
- $3.63
- Volume:
- 5866
Company Statistics
- Market Cap.:
- $11.94 million
- Book Value:
- 13.883
- Revenue TTM:
- $0
- Operating Margin TTM:
- 0%
- Gross Profit TTM:
- $18 million
- Profit Margin:
- 0%
- Return on Assets TTM:
- -30.63%
- Return on Equity TTM:
- -48.7%
Company Profile
Landos Biopharma Inc had its IPO on 2021-02-04 under the ticker symbol LABP.
The company operates in the Healthcare sector and Biotechnology industry. Landos Biopharma Inc has a staff strength of 22 employees.
Stock update
Shares of Landos Biopharma Inc opened at $3.63 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $3.3 - $3.63, and closed at $3.53.
This is a -2.75% slip from the previous day's closing price.
A total volume of 5,866 shares were traded at the close of the day’s session.
In the last one week, shares of Landos Biopharma Inc have slipped by -7.83%.
Landos Biopharma Inc's Key Ratios
Landos Biopharma Inc has a market cap of $11.94 million, indicating a price to book ratio of 0.2437 and a price to sales ratio of 2.3706.
In the last 12-months Landos Biopharma Inc’s revenue was $0 with a gross profit of $18 million and an EBITDA of $-25271500. The EBITDA ratio measures Landos Biopharma Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Landos Biopharma Inc’s operating margin was 0% while its return on assets stood at -30.63% with a return of equity of -48.7%.
In Q2, Landos Biopharma Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.
Landos Biopharma Inc’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0
- PEG
Its diluted EPS in the last 12-months stands at $-4.92 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Landos Biopharma Inc’s profitability.
Landos Biopharma Inc stock is trading at a EV to sales ratio of 0.6668 and a EV to EBITDA ratio of 1.1716. Its price to sales ratio in the trailing 12-months stood at 2.3706.
Landos Biopharma Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $46.29 million
- Total Liabilities
- $3.02 million
- Operating Cash Flow
- $0
- Capital Expenditure
- $0
- Dividend Payout Ratio
- 0%
Landos Biopharma Inc ended 2024 with $46.29 million in total assets and $0 in total liabilities. Its intangible assets were valued at $46.29 million while shareholder equity stood at $43.27 million.
Landos Biopharma Inc ended 2024 with $0 in deferred long-term liabilities, $3.02 million in other current liabilities, 31000.00 in common stock, $-143383000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $44.05 million and cash and short-term investments were $44.74 million. The company’s total short-term debt was $0 while long-term debt stood at $0.
Landos Biopharma Inc’s total current assets stands at $46.29 million while long-term investments were $0 and short-term investments were $687000.00. Its net receivables were $0 compared to accounts payable of $1.03 million and inventory worth $0.
In 2024, Landos Biopharma Inc's operating cash flow was $0 while its capital expenditure stood at $0.
Comparatively, Landos Biopharma Inc paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $3.53
- 52-Week High
- $11.5
- 52-Week Low
- $2.11
- Analyst Target Price
- $5
Landos Biopharma Inc stock is currently trading at $3.53 per share. It touched a 52-week high of $11.5 and a 52-week low of $11.5. Analysts tracking the stock have a 12-month average target price of $5.
Its 50-day moving average was $3.93 and 200-day moving average was $3.53 The short ratio stood at 0.5 indicating a short percent outstanding of 0%.
Around 2952.9% of the company’s stock are held by insiders while 5570.7% are held by institutions.
Frequently Asked Questions About Landos Biopharma Inc
Similar Industry Stocks (Biotechnology)
Most Active
Top Gainers
Top Losers
About
Landos Biopharma, Inc., a clinical-stage biopharmaceutical company, discovers and develops oral therapeutics for patients with autoimmune diseases. Its lead product candidate is NX-13, an oral gut-selective Nucleotide Oligomerization Domain (NLRX1), a mitochondria-associated receptor associated with the modulation of inflammatory cytokines that completed Phase Ib clinical trial to treat ulcerative colitis (UC), as well as induce anti-inflammatory effects in CD4+ T cells and other cells in the gastrointestinal tract. The company’s preclinical candidates in development include LABP-73, an oral and small molecule NLRX1 pathway agonist in development for the treatment of asthma and chronic obstructive pulmonary disease; LABP-66 is an oral and small molecule NLRX1 pathway agonist for the treatment of multiple sclerosis and Alzheimer’s disease; and LABP-69, an oral PLXDC2 agonist for the treatment of diabetic nephropathy and RA. The company was incorporated in 2017 and is headquartered in Blacksburg, Virginia.